
Opinion|Videos|August 14, 2024
When CML Therapy Shifts: Collaborative Approaches to Treatment Changes
Claire Saxton shares insights on how physicians and caregivers can best assist patients with CML who have switched therapies.
Advertisement
Episodes in this series

This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following questions:
- In your experience, how can physicians and caregivers both support patients in navigating a therapy change? Which resources can best help support patients during a treatment transition?
Advertisement
Related to this article

Chemotherapy-free regimens for lymphoma and new drug combinations for myeloma are among the ASH 2026 studies patients should watch.

An expert from Case Western Reserve University explains how cancer cells survive treatment, why rare diseases are hard to study and why CAR-T therapy offers hope.

An Ohio State hematologist discusses a new trial comparing tovorafenib plus rituximab with standard cladribine-based treatment, and what quality of life means for patients.

An Ohio State hematologist explains how she weighs chemotherapy against targeted drugs, what side effects patients should expect and why learning about this specific leukemia matters.
Advertisement
Advertisement

